Viatris names Andrew Enrietti as chief administrative officer

PITTSBURGH - Viatris Inc. (NASDAQ:VTRS), a global healthcare company with a market capitalization of $12.4 billion and annual revenue of $14.1 billion, has appointed Andrew Enrietti to the newly created position of Chief Administrative and Transformation Officer, the global healthcare company announced Tuesday. According to InvestingPro data, the company maintains a "GOOD" overall financial health score, positioning it well for this organizational transformation.

In his new role, Enrietti will oversee Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation aims to centralize leadership of the company’s digital, cultural and structural transformation initiatives. This transformation comes at a crucial time, as InvestingPro analysis shows management has been actively buying back shares, demonstrating confidence in the company’s direction.

Enrietti, who has over 20 years of career experience including 10 years with Viatris and its legacy companies, most recently served as Chief People Officer. He has been involved in numerous business transactions and integrations during his tenure.

"His deep understanding of our organization, combined with his proven ability to deliver results and his people-first leadership style, will be instrumental as we continue to finalize and then execute our enterprise-wide strategic review," said Scott A. Smith, CEO of Viatris, in the press release.

The appointment comes as Viatris continues its strategic evolution aimed at positioning the company for long-term growth. The new organizational structure brings together several critical functions under Enrietti’s leadership.

"The structure we are creating represents a great opportunity to help shape the future of our organization by bringing together critical functions that will drive our transformation," Enrietti stated.

Viatris, headquartered in the U.S. with global centers in Pittsburgh, Shanghai and Hyderabad, supplies medicines to approximately 1 billion patients annually worldwide, according to the company’s statement. The company’s strong market position is reflected in its financial metrics, with analysts expecting net income growth this year. For deeper insights into Viatris’s financial health and market position, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US equities.

In other recent news, Viatris Inc. reported its second-quarter earnings for 2025, exceeding analyst expectations with an earnings per share of $0.62, surpassing the forecasted $0.55. The company also outperformed revenue projections, reporting $3.57 billion against an anticipated $3.47 billion. Additionally, the U.S. Food and Drug Administration approved Viatris’ Iron Sucrose Injection, USP, marking the first generic version of Venofer Injection. This intravenous iron replacement product is designed to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease and will be available in three different strengths. These developments reflect significant progress for Viatris, offering new opportunities in the healthcare market. The recent FDA approval and strong quarterly performance may influence future analyst ratings and investor interest.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.